Menu
 
Research menu
Jump to menu

Publications:  Prof Frances Balkwill

Candido JB, Morton JP, Bailey P et al.(2018). CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype. Cell Rep vol. 23, (5) 1448-1460.
10.1016/j.celrep.2018.03.131
http://qmro.qmul.ac.uk/xmlui/handle/123456789/36702
Pearce OMT, Delaine-Smith R, Maniati E et al.(2017). Deconstruction of a metastatic tumor microenvironment reveals a common matrix response in human cancers. Cancer Discov
10.1158/2159-8290.CD-17-0284
http://qmro.qmul.ac.uk/xmlui/handle/123456789/30984
McDermott JR, Jones R, Lockley M et al. (2017). The Chemokine CXCL10 is a Potential Regulator of Cancer Stem Cells in High Grade Serous Carcinoma. JOURNAL OF PATHOLOGY. vol. 243, S15-S15.
Naba A, Pearce OMT, Del Rosario A et al.(2017). Characterization of the Extracellular Matrix of Normal and Diseased Tissues Using Proteomics. J Proteome Res vol. 16, (8) 3083-3091.
10.1021/acs.jproteome.7b00191
http://qmro.qmul.ac.uk/xmlui/handle/123456789/25021
Netea MG, Balkwill F, Chonchol M et al.(2017). A guiding map for inflammation. Nat Immunol vol. 18, (8) 826-831.
10.1038/ni.3790
http://qmro.qmul.ac.uk/xmlui/handle/123456789/25129
McCarthy FM, Candido J, Rudd R et al. (2017). Upregulation of amphiregulin on CD14++CD16-(classical) monocytes in non-small cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY. vol. 35,
10.1200/JCO.2017.35.15_suppl.e14612
BALKWILL F, Berlato C, Khan MN et al.(2017). A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer. Journal of Clinical Investigation
10.1172/JCI82976
http://qmro.qmul.ac.uk/xmlui/handle/123456789/18188
Walton J, Blagih J, Ennis D et al.(2016). CRISPR/Cas9-mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian high grade serous carcinoma. Cancer Research
10.1158/0008-5472.CAN-16-1272
http://qmro.qmul.ac.uk/xmlui/handle/123456789/25148
Delaine-Smith RM, Burney S, Balkwill FR et al.(2016). Experimental validation of a flat punch indentation methodology calibrated against unconfined compression tests for determination of soft tissue biomechanics. Journal of the Mechanical Behavior of Biomedical Materials vol. 60, 401-415.
10.1016/j.jmbbm.2016.02.019
Montfort A, Pearce OMT, Maniati E et al.(2016). A strong B cell response is part of the immune landscape in human high-grade serous ovarian metastases. Clinical Cancer Research
10.1158/1078-0432.CCR-16-0081
http://qmro.qmul.ac.uk/xmlui/handle/123456789/13383
Steele CW, Karim SA, Leach JDG et al.(2016). CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. Cancer Cell vol. 29, (6) 832-845.
10.1016/j.ccell.2016.04.014
GROSE RP, Dawkins JBN, Wang J et al.(2016). Reduced expression of histone methyltransferases KMT2C and KMT2D correlates with improved outcome in pancreatic ductal adenocarcinoma. Cancer Research
10.1158/0008-5472.CAN-16-0481
http://qmro.qmul.ac.uk/xmlui/handle/123456789/12978
BALKWILL F, Anne Montfort, Oliver Pearce(2016). Neoadjuvant chemotherapy modulates the immune microenvironment in metastases of tubo-ovarian high-grade serous carcinoma. Clinical Cancer Research
10.1158/1078-0432.CCR-15-2657
http://qmro.qmul.ac.uk/xmlui/handle/123456789/13991
Kulbe H, Iorio F, Chakravarty P et al.(2016). Integrated transcriptomic and proteomic analysis identifies protein kinase CK2 as a key signaling node in an inflammatory cytokine network in ovarian cancer cells. Oncotarget vol. 7, (13) 15648-15661.
10.18632/oncotarget.7255
http://qmro.qmul.ac.uk/xmlui/handle/123456789/22200
Walton J, Dowson S, Ennis D et al.(2016). CRISPR/Cas9 mediated p53 and BRCA2 knockout to generate improved murine models of high grade serous ovarian cancer. CLINICAL CANCER RESEARCH vol. 22,
10.1158/1557-3265.OVCA15-B53
Tamura N, Shaikh N, McGuinness JR et al. (2016). What drives chromosomal instability in high-grade serous ovarian cancer?. MOLECULAR BIOLOGY OF THE CELL. vol. 27,
Bowtell DD, Böhm S, Ahmed AA et al.(2015). Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer vol. 15, (11) 668-679.
10.1038/nrc4019
Crusz SM, Balkwill FR(2015). Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol vol. 12, (10) 584-596.
10.1038/nrclinonc.2015.105
http://qmro.qmul.ac.uk/xmlui/handle/123456789/9142
Montfort A, Boehm S, Dowe T et al. (2015). B cells actively participate to the anti-cancer immune response in high grade serous ovarian cancer metastases. CANCER RESEARCH. vol. 75,
10.1158/1538-7445.AM2015-455
Gopinathan G, Milagre C, Pearce OMT et al.(2015). Interleukin-6 Stimulates Defective Angiogenesis. Cancer Res vol. 75, (15) 3098-3107.
10.1158/0008-5472.CAN-15-1227
Gopinathan G, Milagre C, Pearce OMT et al.(2015). Interleukin-6 stimulates defective angiogenesis. CANCER RESEARCH vol. 75,
10.1158/1538-7445.AM2015-4162
Milagre CS, Gopinathan G, Everitt G et al.(2015). Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer. Cancer Res vol. 75, (7) 1255-1264.
10.1158/0008-5472.CAN-14-1801
http://qmro.qmul.ac.uk/xmlui/handle/123456789/7203
Balkwill F(2015). Targeting inflammatory cytokines in cancer. CLINICAL & EXPERIMENTAL METASTASIS vol. 32, (3) 183-183.
Balkwill F, Chambers K(2015). Centre of the Cell: Science Comes to Life. PLoS Biol vol. 13, (9)
10.1371/journal.pbio.1002240
Balkwill F (2014). Targeting inflammatory cytokines in cancer. CYTOKINE. vol. 70, 21-21.
10.1016/j.cyto.2014.07.224
http://qmro.qmul.ac.uk/xmlui/handle/123456789/7038
Berlato C, Kahn MN, Schioppa T et al. (2014). Antagonists of the chemokine receptor CCR4 reverse the tumor-promoting microenvironment of renal cancer. CANCER RESEARCH. vol. 74,
10.1158/1538-7445.AM2014-1076
Rei M, Gonçalves-Sousa N, Lança T et al.(2014). Murine CD27(-) Vγ6(+) γδ T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophages. Proc Natl Acad Sci U S A vol. 111, (34) E3562-E3570.
10.1073/pnas.1403424111
Balkwill F(2014). Targeting cancer-related inflammation. EUROPEAN JOURNAL OF CANCER vol. 50, S9-S9.
10.1016/S0959-8049(14)50033-0
Karin M, Jobin C, Balkwill F(2014). Chemotherapy, immunity and microbiota--a new triumvirate?. Nat Med vol. 20, (2) 126-127.
10.1038/nm.3473
Lau T-S, Chung TK-H, Cheung T-H et al.(2014). Cancer cell-derived lymphotoxin mediates reciprocal tumour-stromal interactions in human ovarian cancer by inducing CXCL11 in fibroblasts. J Pathol vol. 232, (1) 43-56.
10.1002/path.4258
Rei M, Lanca T, Thompson R et al. (2013). Major contribution of gamma delta T cells to IL-17A production and ovarian cancer cell growth in vivo. IMMUNOLOGY. vol. 140, 160-160.
Whilding LM, Archibald KM, Kulbe H et al.(2013). Vaccinia virus induces programmed necrosis in ovarian cancer cells. Mol Ther vol. 21, (11) 2074-2086.
10.1038/mt.2013.195
Leinster DA, Colom B, Whiteford JR et al.(2013). Endothelial cell junctional adhesion molecule C plays a key role in the development of tumors in a murine model of ovarian cancer. FASEB J vol. 27, (10) 4244-4253.
10.1096/fj.13-230441
Boehm S, Ennis D, Dowe T et al. (2013). Tumour-associated inflammatory cytokines are reduced following primary platinum-based chemotherapy in plasma of high-grade serous ovarian cancer patients. EUROPEAN JOURNAL OF CANCER. vol. 49, S736-S736.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/7136
Sandhu SK, Papadopoulos K, Fong PC et al.(2013). A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. Cancer Chemother Pharmacol vol. 71, (4) 1041-1050.
10.1007/s00280-013-2099-8
Balkwill F, Montfort A, Capasso M(2013). B regulatory cells in cancer. Trends Immunol vol. 34, (4) 169-173.
10.1016/j.it.2012.10.007
Balkwill FR, Capasso M, Hagemann T(2012). The tumor microenvironment at a glance. J Cell Sci vol. 125, (Pt 23) 5591-5596.
10.1242/jcs.116392
Archibald KM, Kulbe H, Kwong J et al.(2012). Sequential genetic change at the TP53 and chemokine receptor CXCR4 locus during transformation of human ovarian surface epithelium. Oncogene vol. 31, (48) 4987-4995.
10.1038/onc.2011.653
Balkwill F (2012). Targeting Cytokine Networks in Malignancy. EUROPEAN JOURNAL OF CANCER. vol. 48, S10-S10.
10.1016/S0959-8049(12)70746-3
Leinster DA, Kulbe H, Everitt G et al.(2012). The peritoneal tumour microenvironment of high-grade serous ovarian cancer. J Pathol vol. 227, (2) 136-145.
10.1002/path.4002
http://qmro.qmul.ac.uk/xmlui/handle/123456789/13856
Affara NI, Ruffell B, Johansson M et al.(2012). CD20 as a target for therapy in solid tumors. CANCER RESEARCH vol. 72,
10.1158/1538-7445.AM2012-4391
Kulbe H, Chakravarty P, Moore R et al.(2012). Targeting the TNF network in human ovarian cancer - A systems biology approach. CANCER RESEARCH vol. 72,
10.1158/1538-7445.AM2012-49
Stone RL, Nick AM, McNeish IA et al.(2012). Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med vol. 366, (7) 610-618.
10.1056/NEJMoa1110352
Balkwill FR, Mantovani A(2012). Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol vol. 22, (1) 33-40.
10.1016/j.semcancer.2011.12.005
Kulbe H, Chakravarty P, Leinster DA et al.(2012). A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res vol. 72, (1) 66-75.
10.1158/0008-5472.CAN-11-2178
Balkwill FR(2012). The chemokine system and cancer. J Pathol vol. 226, (2) 148-157.
10.1002/path.3029
Balkwill FR, Coward J, Kulbe H et al.(2011). IL-6 and ovarian cancer--response. Clin Cancer Res vol. 17, (24)
10.1158/1078-0432.CCR-11-2680
Maniati E, Bossard M, Cook N et al. (2011). Cross-talk between IKK2 and Notch promotes pancreatic cancer progression in mice through Hes1 mediated PPAR gamma inhibitio. IMMUNOLOGY. vol. 135, 169-169.
Maniati E, Bossard M, Cook N et al.(2011). Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice. J Clin Invest vol. 121, (12) 4685-4699.
10.1172/JCI45797
Coward J, Balkwill F(2011). Targeting inflammatory pathways in epithelial ovarian cancer. Emerging Therapeutic Targets in Ovarian Cancer,
Balkwill F(2011). The inflammatory tissue microenvironment and the early stages of malignancy. Pre-Invasive Disease: Pathogenesis and Clinical Management,
Rei M, Lanca T, King E et al. (2011). Understanding the dual role of murine gamma delta T cells in tumour surveillance and tumour progression. IMMUNOLOGY. vol. 135, 146-146.
Balkwill F (2011). Inflammatory cytokines and autocrine tumour-promoting networks. CYTOKINE. vol. 56, 51-51.
10.1016/j.cyto.2011.07.338
Vaughan S, Coward JI, Bast RC et al.(2011). Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer vol. 11, (10) 719-725.
10.1038/nrc3144
Coward J, Kulbe H, Chakravarty P et al.(2011). Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res vol. 17, (18) 6083-6096.
10.1158/1078-0432.CCR-11-0945
Balkwill F, Whitehead S, Willis P et al.(2011). Safety of medicines and the use of animals in research. Lancet vol. 378, (9786) 127-128.
10.1016/S0140-6736(11)60984-7
Schioppa T, Moore R, Thompson RG et al.(2011). B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis. Proc Natl Acad Sci U S A vol. 108, (26) 10662-10667.
10.1073/pnas.1100994108
Balkwill F (2011). INFLAMMATORY CYTOKINES AND AUTOCRINE TUMOR-PROMOTING NETWORKS. INFLAMMATION RESEARCH. vol. 60, 26-26.
Allan S, Balkwill F(2011). Translating science in more ways than one: an interview with Frances Balkwill. DIS MODEL MECH vol. 4, (3) 286-288.
10.1242/dmm.007898
Anglesio MS, George J, Kulbe H et al.(2011). IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res vol. 17, (8) 2538-2548.
10.1158/1078-0432.CCR-10-3314
Salako MA, Kulbe H, Ingemarsdotter CK et al.(2011). Inhibition of the inflammatory cytokine TNF-α increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression. Mol Ther vol. 19, (3) 490-499.
10.1038/mt.2010.247
Balkwill F (2011). MECHANISMS OF THE TUMOR-PROMOTING ACTION OF TNF-alpha IN EPITHELIAL TUMORS. ADVANCES IN TNF FAMILY RESEARCH. Editors: Wallach, D, Kovalenko, A, Feldman, M, vol. 691, 653-654.
Schioppa T, Moore R, Thompson R et al. (2011). ROLE OF B CELL IN TWO-STAGE SKIN CARCINOGENESIS. ADVANCES IN TNF FAMILY RESEARCH. Editors: Wallach, D, Kovalenko, A, Feldman, M, vol. 691, 755-756.
Balkwill F (2010). Inflammatory cytokines and autocrine tumor-promoting networks. IMMUNOLOGY. vol. 131, 3-3.
Balkwill F, Joffroy C(2010). TNF: a tumor-suppressing factor or a tumor-promoting factor?. Future Oncol vol. 6, (12) 1833-1836.
10.2217/fon.10.155
Flak MB, Connell CM, Chelala C et al.(2010). p21 Promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker. Mol Cancer vol. 9,
10.1186/1476-4598-9-175
http://qmro.qmul.ac.uk/xmlui/handle/123456789/13470
Toulza F, Nosaka K, Tanaka Y et al.(2010). Human T-lymphotropic virus type 1-induced CC chemokine ligand 22 maintains a high frequency of functional FoxP3+ regulatory T cells. J Immunol vol. 185, (1) 183-189.
10.4049/jimmunol.0903846
Workman P, Aboagye EO, Balkwill F et al.(2010). Guidelines for the welfare and use of animals in cancer research. Br J Cancer vol. 102, (11) 1555-1577.
10.1038/sj.bjc.6605642
Coward JI, Kulbe H, Leader D et al. (2010). Interleukin-6 as a therapeutic target in advanced ovarian cancer. JOURNAL OF CLINICAL ONCOLOGY. vol. 28,
10.1200/jco.2010.28.15_suppl.5089
Forster MD, Patnaik A, Sandhu SK et al. (2010). Pre-final analysis of first-in-human, first-in-class, phase I clinical trial of CNTO 888, a human monoclonal antibody to the CC-chemokine ligand 2 (CCL2) in patients (pts) with advanced solid tumors. JOURNAL OF CLINICAL ONCOLOGY. vol. 28,
10.1200/jco.2010.28.15_suppl.2548
Balkwill F, Mantovani A(2010). Cancer and inflammation: implications for pharmacology and therapeutics. Clin Pharmacol Ther vol. 87, (4) 401-406.
10.1038/clpt.2009.312
Coward J, Kulbe H, Leader D et al. (2010). Interleukin-6 as a therapeutic target in advanced ovarian cancer. CANCER RESEARCH. vol. 70,
10.1158/1538-7445.AM10-5331
Saadi A, Shannon NB, Lao-Sirieix P et al.(2010). Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. Proc Natl Acad Sci U S A vol. 107, (5) 2177-2182.
10.1073/pnas.0909797107
Balkwill F, Mantovani A(2010). Foreword. Cytokine Growth Factor Rev vol. 21, (1)
10.1016/j.cytogfr.2009.11.004
Sandhu SK, Fong PC, Patnaik A et al. (2009). First-in-man, first-in-class, pharmacokinetic and pharmacodynamic phase I clinical trial of a human monoclonal antibody CNT0888 to CC-chemokine ligand 2 (CCL2) / monocyte chemoattractant protein (MCP-1) in patients with advanced solid tumors. MOLECULAR CANCER THERAPEUTICS. vol. 8,
10.1158/1535-7163.TARG-09-A102
Charles KA, Kulbe H, Soper R et al.(2009). The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest vol. 119, (10) 3011-3023.
10.1172/JCI39065
Kwong J, Kulbe H, Wong D et al.(2009). An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells. Mol Cancer Ther vol. 8, (7) 1893-1905.
10.1158/1535-7163.MCT-08-0966
Kwong J, Chan FL, Wong K-K et al.(2009). Inflammatory cytokine tumor necrosis factor alpha confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells. Neoplasia vol. 11, (6) 529-541.
10.1593/neo.09112
Coward J, Quigley M, Leader D et al.(2009). A Phase II study of intravenous CNT0328 in patients with recurrent epithelial ovarian cancer. CANCER RESEARCH vol. 69,
Kulbe H, Leinster A, Chakravarty P et al. (2009). An autocrine cytokine network in ovarian cancer that influences patient survival. CANCER RESEARCH. vol. 69,
Balkwill FR (2009). CHEMOKINE RECEPTORS AND INFLAMMATION IN CANCER. ANNALS OF ONCOLOGY. vol. 20, 17-17.
Schioppa T, Moore R, Thompson R et al.(2009). Role of B cell in two-stage skin carcinogenesis. CANCER RESEARCH vol. 69,
Archibald K, Kwong J, Kulbe H et al.(2009). Spontaneously transformed hTERT immortalized human ovarian surface epithelial cells have a functional amplification of the CXCR4 gene locus. CANCER RESEARCH vol. 69,
Balkwill F(2009). Tumour necrosis factor and cancer. Nat Rev Cancer vol. 9, (5) 361-371.
10.1038/nrc2628
Li NF, Kocher HM, Salako MA et al.(2009). A novel function of colony-stimulating factor 1 receptor in hTERT immortalization of human epithelial cells. Oncogene vol. 28, (5) 773-780.
10.1038/onc.2008.412
Mantovani A, Allavena P, Sica A et al.(2008). Cancer-related inflammation. Nature vol. 454, (7203) 436-444.
10.1038/nature07205
Brown ER, Charles KA, Hoare SA et al.(2008). A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. ANN ONCOL vol. 19, (7) 1340-1346.
10.1093/annonc/mdn054
Hagemann T, Lawrence T, McNeish I et al.(2008). "Re-educating" tumor-associated macrophages by targeting NF-kappaB. J Exp Med vol. 205, (6) 1261-1268.
10.1084/jem.20080108
Ashworth A, Balkwill F, Bast RC et al.(2008). Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007. GYNECOL ONCOL vol. 108, (3) 652-657.
10.1016/j.ygyno.2007.11.014
Karagiannis SN, Bracher MG, Beavil RL et al.(2008). Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells. CANCER IMMUNOL IMMUN vol. 57, (2) 247-263.
10.1007/s00262-007-0371-7
Harrison ML, Obermueller E, Maisey NR et al. (2007). Tumor necrosis factor alpha as a new target for renal cell carcinoma: Two sequential phase II trials of infliximab at standard and high dose. JOURNAL OF CLINICAL ONCOLOGY. vol. 25, 4542-4549.
10.1200/JCO.2007.11.2136
Li NF, Broad S, Lu YJ et al.(2007). Human ovarian surface epithelial cells immortalized with hTERT maintain functional pRb and p53 expression. Cell Prolif vol. 40, (5) 780-794.
10.1111/j.1365-2184.2007.00462.x
Hagemann T, Balkwill F, Lawrence T(2007). Inflammation and cancer: A double-edged sword. CANCER CELL vol. 12, (4) 300-301.
10.1016/j.ccr.2007.10.005
Karagiannis SN, Bracher MG, Hunt J et al.(2007). IgE-antibody-dependent immunotherapy of solid tumors: Cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells. J IMMUNOL vol. 179, (5) 2832-2843.
10.4049/jimmunol.179.5.2832
Lawrence T, Hageman T, Balkwill F(2007). Cancer. Sex, cytokines, and cancer. Science vol. 317, (5834) 51-52.
10.1126/science.1146052
Szlosarek PW, Grimshaw MJ, Wilbanks GD et al.(2007). Aberrant regulation of argininosuccinate synthetase by TNF-alpha in human epithelial ovarian cancer. Int J Cancer vol. 121, (1) 6-11.
10.1002/ijc.22666
Hagemann T, Robinson SC, Thompson RG et al.(2007). Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. Mol Cancer Ther vol. 6, (7) 1993-2002.
10.1158/1535-7163.MCT-07-0118
Kulbe H, Thompson R, Wilson JL et al.(2007). The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. CANCER RES vol. 67, (2) 585-592.
10.1158/0008-5472.CAN-06-2941
Lawrence T, Fong C, Bebien M et al. (2007). IKKbeta inhibits 'Classical' macrophage activation in innate immunity and cancer. JOURNAL OF LEUKOCYTE BIOLOGY. 41-41.
Szlosarek PW, Klabatsa A, Pallaska A et al.(2006). In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. CLIN CANCER RES vol. 12, (23) 7126-7131.
10.1158/1078-0432.CCR-06-1101
Mantovani A, Balkwill F(2006). RaIB signaling: A bridge between inflammation and cancer. CELL vol. 127, (1) 42-44.
10.1016/j.cell.2006.09.019
Direkze NC, Jeffery R, Hodivala-Dilke K et al. (2006). Bone marrow contributes to functionally active cells in tumour stroma. JOURNAL OF PATHOLOGY. vol. 210, 1-1.
Balkwill F(2006). TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev vol. 25, (3) 409-416.
10.1007/s10555-006-9005-3
Strauss SJ, Maharaj L, Hoare S et al.(2006). Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol vol. 24, (13) 2105-2112.
10.1200/JCO.2005.04.6789
Hagemann T, Wilson J, Burke F et al.(2006). Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol vol. 176, (8) 5023-5032.
10.4049/jimmunol.176.8.5023
Hagemann T, Wilson J, Burke F et al.(2006). Ovarian cancer cells polarize macrophages towards a tumor-associated phenotype. MED KLIN vol. 101, (4) A44-A44.
Balkwill F(2006). Cancer and inflammation. EUR J CANCER vol. 42, (6) 689-690.
10.1016/j.ejca.2006.03.002
Szlosarek P, Charles KA, Balkwill FR(2006). Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer vol. 42, (6) 745-750.
10.1016/j.ejca.2006.01.012
Balkwill FR, Ashworth A, Bast RC et al.(2006). 10th Biennial Helene Harris Memorial Trust meeting. Cancer Res vol. 66, (6) 2904-2906.
10.1158/0008-5472.CAN-05-2093
Balkwill F(2006). Inflammation: a double-edged sword. EUR J CANCER vol. 42, (5) 571-571.
Szlosarek PW, Grimshaw MJ, Kulbe H et al.(2006). Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium. MOL CANCER THER vol. 5, (2) 382-390.
10.1158/1535-7163.MCT-05-0303
Kulbe H, Hagemann T, Szlosarek PW et al.(2005). The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells. CANCER RES vol. 65, (22) 10355-10362.
10.1158/0008-5472.CAN-05-0957
Hagemann T, Balkwill F(2005). MIFed about cancer?. GASTROENTEROLOGY vol. 129, (5) 1785-1787.
10.1053/j.gastro.2005.09.039
Madhusudan S, Muthuramalingam SR, Braybrooke JP et al.(2005). Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. J Clin Oncol vol. 23, (25) 5950-5959.
10.1200/JCO.2005.04.127
Hagemann T, Wilson J, Kulbe H et al.(2005). Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol vol. 175, (2) 1197-1205.
10.4049/jimmunol.175.2.1197
Barton C, Davies D, Balkwill F et al.(2005). Involvement of both intrinsic and extrinsic pathways in IFN-gamma-induced apoptosis that are enhanced with cisplatin. Eur J Cancer vol. 41, (10) 1474-1486.
10.1016/j.ejca.2005.03.022
Balkwill F(2005). The language of life: How cells communicate in health and disease. NATURE vol. 435, (7046) 1162-1162.
10.1038/4351162a
Strauss S, Maharaj L, Hoare S et al. (2005). Bortezomib (VELCADE (R)) in patients with relapsed/refractory lymphoma: Potential correlation of TNF alpha response and in vitro sensitivity with clinical activity. ANNALS OF ONCOLOGY. vol. 16, 65-65.
Balkwill F(2005). Immunology for the next generation. Nat Rev Immunol vol. 5, (6) 509-512.
10.1038/nri1628
Direkze N, Jeffery R, Hodivala-Dilke K et al. (2005). Bone marrow contributes functionally active cell types to tumour stroma. GASTROENTEROLOGY. vol. 128, A182-A182.
Direkze NC, Jeffery R, Hodivala-Dilke K et al. (2005). Bone marrow contributes to functionally active cells in tumour stroma. GUT. vol. 54, A24-A24.
Balkwill F, Watt F(2005). Fran Balkwill. J Cell Sci vol. 118, (Pt 7) 1339-1340.
10.1242/jcs.01688
Balkwill F, Charles KA, Mantovani A(2005). Smoldering and polarized inflammation in the initiation and promotion of malignant disease. CANCER CELL vol. 7, (3) 211-217.
10.1016/j.ccr.2005.02.013
Thun MJ, Feldmann M, Ristimäki A et al. (2004). Discussion. Novartis Foundation Symposium. vol. 256, 69-73.
D'Incalci M, Strieter RM, Mantovani A et al. (2004). Final general discussion. Novartis Foundation Symposium. vol. 256, 259-265.
Smyth J, Rollins B, Harris A et al. (2004). General discussion I. Novartis Foundation Symposium. vol. 256, 49-52.
Balkwill FR (2004). The inflammatory cytokine network and the development of epithelial cancer. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION. vol. 13, 1958S-1958S.
Madhusudan S, Foster M, Muthuramalingam SR et al.(2004). A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin Cancer Res vol. 10, (19) 6528-6534.
10.1158/1078-0432.CCR-04-0730
Balkwill F, Coussens LM(2004). Cancer - An inflammatory link. NATURE vol. 431, (7007) 405-406.
10.1038/431405a
Scott KA, Arnott CH, Robinson SC et al.(2004). TNF-alpha regulates epithelial expression of MMP-9 and integrin alphavbeta6 during tumour promotion. A role for TNF-alpha in keratinocyte migration?. Oncogene vol. 23, (41) 6954-6966.
10.1038/sj.onc.1207915
Hagemann T, Robinson SC, Schulz M et al.(2004). Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis vol. 25, (8) 1543-1549.
10.1093/carcin/bgh146
Jones PH, Christodoulos K, Dobbs N et al.(2004). Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer. Br J Cancer vol. 91, (1) 30-36.
10.1038/sj.bjc.6601897
Li NF, Wilbanks G, Balkwill F et al.(2004). A modified medium that significantly improves the growth of human normal ovarian surface epithelial (OSE) cells in vitro. Lab Invest vol. 84, (7) 923-931.
10.1038/labinvest.3700093
Balkwill F(2004). Cancer and the chemokine network. NAT REV CANCER vol. 4, (7) 540-550.
10.1038/nrc1388
Li N, Wilbanks G, Dafou D et al. (2004). Establishing cellular model for studying the carcinogenesis of human ovarian epithelium. BRITISH JOURNAL OF CANCER. vol. 91, S74-S74.
Szlosarek PW, Grimshaw MJ, Wilbanks GD et al. (2004). Regulation and expression of argininosuccinate synthetase in human ovarian cancer. BRITISH JOURNAL OF CANCER. vol. 91, S57-S57.
Kulbe H, Wilson JL, Balkwill FR (2004). Transfection of the chemokine receptor CXCR4 alters the behavior of ovarian cancer cells in vitro and in vivo. BRITISH JOURNAL OF CANCER. vol. 91, S74-S74.
Balkwill F(2004). The significance of cancer cell expression of the chemokine receptor CXCR4. SEMIN CANCER BIOL vol. 14, (3) 171-179.
10.1016/j.semcancer.2003.10.003
Grimshaw MJ, Hagemann T, Ayhan A et al.(2004). A role for endothelin-2 and its receptors in breast tumor cell invasion. Cancer Res vol. 64, (7) 2461-2468.
10.1158/0008-5472.CAN-03-1069
Arnott CH, Scott KA, Moore RJ et al.(2004). Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development. Oncogene vol. 23, (10) 1902-1910.
10.1038/sj.onc.1207317
Balkwill F, Bast RC, Berek J et al.(2004). Current research and treatment for epithelial ovarian cancer. A position paper from the Helene Harris Memorial Trust (vol 39, pg 1818, 2003). EUR J CANCER vol. 40, (4) 628-628.
10.1016/j.ejca.2003.11.005
Kulbe H, Levinson NR, Balkwill F et al.(2004). The chemokine network in cancer - much more than directing cell movement. INT J DEV BIOL vol. 48, (5-6) 489-496.
10.1387/ijdb.041814hk
Szlosarek P, Balkwill F(2004). The inflammatory cytokine network of epithelial cancer: therapeutic implications. Novartis Found Symp vol. 256, 227-237.
Robinson SC, Scott KA, Wilson JL et al.(2003). A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res vol. 63, (23) 8360-8365.
Madhusudan S, Braybrooke JP, Forster M et al. (2003). A phase II Trial of etanercept a recombinant human soluble tumour necrosis factor receptor (p75) fusion protein in patients with metastatic breast cancer. CLINICAL CANCER RESEARCH. vol. 9, 6192S-6192S.
Arnott CH, Scott KA, Moore RJ et al. (2003). Expression of both TNFR1 and TNFR2 is essential for optimal TNF-alpha-mediated skin tumor development. CLINICAL CANCER RESEARCH. vol. 9, 6212S-6212S.
Balkwill F (2003). Inhibiting inflammatory cytokines and chemokines in the tumour microenvironment. JOURNAL OF IMMUNOTHERAPY. vol. 26, S26-S27.
Madhusudan S, Protheroe A, Propper D et al.(2003). A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer. BRIT J CANCER vol. 89, (8) 1418-1422.
10.1038/sj.bjc.6601321
Balkwill F, Bast RC, Berek J et al.(2003). Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust. Eur J Cancer vol. 39, (13) 1818-1827.
10.1016/S0959-8049(03)00511-2
Szlosarek PW, Balkwill FR(2003). Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol vol. 4, (9) 565-573.
10.1016/S1470-2045(03)01196-3
Ramalingam S, Hoare S, Madhusudan S et al. (2003). A phase II trial of etanercept, a tumour necrosis factor-alpha inhibitor in recurrent ovarian cancer. BRITISH JOURNAL OF CANCER. vol. 88, S57-S57.
Wall L, Burke F, Barton C et al.(2003). IFN-gamma induces apoptosis in ovarian cancer cells in vivo and in vitro. Clin Cancer Res vol. 9, (7) 2487-2496.
Wall L, Burke F, Barton C et al.(2003). IFN-γ induces apoptosis in ovarian cancer cells in vivo and in vitro. Clinical Cancer Research vol. 9, (7) 2487-2496.
Scott KA, Moore RJ, Arnott CH et al.(2003). An anti-tumor necrosis factor-alpha antibody inhibits the development of experimental skin tumors. Mol Cancer Ther vol. 2, (5) 445-451.
Karagiannis SN, Wang Q, East N et al.(2003). Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. EUR J IMMUNOL vol. 33, (4) 1030-1040.
10.1002/eji.200323185
Balkwill F(2003). Chemokine biology in cancer. SEMIN IMMUNOL vol. 15, (1) 49-55.
10.1016/S1044-5323(02)00127-6
Balkwill F, Schlom J, Berek J et al. (2003). Discussion: Immunological therapeutics in ovarian cancer. GYNECOLOGIC ONCOLOGY. vol. 88, S110-S113.
10.1002/gyno.2002.6696
Propper DJ, Chao D, Braybrooke JP et al.(2003). Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma. CLIN CANCER RES vol. 9, (1) 84-92.
Wall L, Burke F, Smyth JF et al. (2003). The anti-proliferative activity of interferon-gamma on ovarian cancer: In vitro and in vivo. GYNECOLOGIC ONCOLOGY. vol. 88, S149-S151.
10.1006/gyno.2002.6707
Wall L, Burke F, Smyth JF et al.(2003). The anti-proliferative activity of interferon-gamma on ovarian cancer: in vitro and in vivo. Gynecologic oncology vol. 88, (1 Pt 2)
Grimshaw MJ, Naylor S, Balkwill FR(2002). Endothelin-2 is a hypoxia-induced autocrine survival factor for breast tumor cells. Mol Cancer Ther vol. 1, (14) 1273-1281.
Ganesan T, Madhusudan S, Braybrooke J et al. (2002). A phase II trial of etanercept, a tumour necrosis factor-a inhibitor in recurrent ovarian cancer. EUROPEAN JOURNAL OF CANCER. vol. 38, S140-S140.
Scotton CJ, Wilson JL, Scott K et al.(2002). Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. CANCER RES vol. 62, (20) 5930-5938.
Grimshaw MJ, Wilson JL, Balkwill FR(2002). Endothelin-2 is a macrophage chemoattractant: Implications for macrophage distribution in tumors. European Journal of Immunology vol. 32, (9) 2393-2400.
10.1002/1521-4141(200209)32:9<2393::AID-IMMU2393>3.0.CO;2-4
Grimshaw MJ, Wilson JL, Balkwill FR(2002). Endothelin-2 is a macrophage chemoattractant: implications for macrophage distribution in tumors. EUR J IMMUNOL vol. 32, (9) 2393-2400.
10.1002/1521-4141(200209)32:9<2393::AID-IMMU2393>3.0.CO;2-4
Arnott CH, Scott KA, Moore RJ et al.(2002). Tumour necrosis factor-alpha mediates tumour promotion via a PKC alpha- and AP-1-dependent pathway. Oncogene vol. 21, (31) 4728-4738.
10.1038/sj.onc.1205588
Forster MD, Braybrooke J, Madhusudan S et al.(2002). A phase II trial using etanercept, a recombinant tumour necrosis factor antagonist, in metastatic breast cancer. BRIT J CANCER vol. 86, S38-S38.
Wall L, Burke F, Smyth J et al.(2002). Characterisation of the cell content of malignant ascites in advanced epithelial ovarian cancer and clinico-pathological correlations. BRIT J CANCER vol. 86, S45-S46.
Milliken D, Scotton C, Raju S et al.(2002). Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites. CLIN CANCER RES vol. 8, (4) 1108-1114.
Wilson J, Balkwill F(2002). The role of cytokines in the epithelial cancer microenvironment. SEMIN CANCER BIOL vol. 12, (2) 113-120.
10.1006/scbi.2001.0419
Balkwill F(2002). Tumor necrosis factor or tumor promoting factor?. Cytokine Growth Factor Rev vol. 13, (2) 135-141.
10.1016/S1359-6101(01)00020-X
Robinson SC, Scott KA, Balkwill FR(2002). Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous TNF-α. European Journal of Immunology vol. 32, (2) 404-412.
10.1002/1521-4141(200202)32:2&lt;404::AID-IMMU404&gt;3.0.CO;2-X
Robinson SC, Scott KA, Balkwill FR(2002). Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous TNF-alpha. Eur J Immunol vol. 32, (2) 404-412.
10.1002/1521-4141(200202)32:2<404::AID-IMMU404>3.0.CO;2-X
Balkwill F(2001). The science book. NATURE vol. 414, (6866) 849-850.
10.1038/414849a
Scotton C, Milliken D, Wilson J et al.(2001). Analysis of CC chemokine and chemokine receptor expression in solid ovarian tumours. Br J Cancer vol. 85, (6) 891-897.
10.1054/bjoc.2001.2020
Scotton CJ, Wilson JL, Milliken D et al.(2001). Epithelial cancer cell migration: a role for chemokine receptors?. Cancer Res vol. 61, (13) 4961-4965.
Grimsha MJ, Balkwill FR(2001). Inhibition of monocyte and macrophage chemotaxis by hypoxia and inflammation - A potential mechanism. BRIT J CANCER vol. 85, 19-19.
Grimshaw MJ, Balkwill FR(2001). Inhibition of monocyte and macrophage chemotaxis by hypoxia and inflammation - A potential mechanism. European Journal of Immunology vol. 31, (2) 480-489.
10.1002/1521-4141(200102)31:2&lt;480::AID-IMMU480&gt;3.0.CO;2-L
Propper DJ, McDonald AC, Man A et al.(2001). Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol vol. 19, (5) 1485-1492.
10.1200/JCO.2001.19.5.1485
Balkwill F, Mantovani A(2001). Inflammation and cancer: back to Virchow?. LANCET vol. 357, (9255) 539-545.
10.1016/S0140-6736(00)04046-0
Grimshaw MJ, Balkwill FR(2001). Inhibition of monocyte and macrophage chemotaxis by hypoxia and inflammation - a potential mechanism. EUR J IMMUNOL vol. 31, (2) 480-489.
10.1002/1521-4141(200102)31:2<480::AID-IMMU480>3.0.CO;2-L
Jankowski JA, Harrison RF, Perry I et al.(2000). Barrett's metaplasia. LANCET vol. 356, (9247) 2079-2085.
10.1016/S0140-6736(00)03411-5
Scott KA, Holdsworth H, Balkwill FR et al.(2000). Exploiting changes in the tumour microenvironment with sequential cytokine and matrix metalloprotease inhibitor treatment in a murine breast cancer model. Br J Cancer vol. 83, (11) 1538-1543.
10.1054/bjoc.2000.1487
Balkwill F, Foxwell B, Brennan F (2000). TNF is here to stay!. Immunol Today. vol. 21, 470-471.
10.1016/S0167-5699(00)01722-9
Balkwill FR(2000). Re: Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst vol. 92, (2) 162-163.
10.1093/jnci/92.2.162A
Sica A, Saccani A, Bottazzi B et al.(2000). Defective expression of the monocyte chemotactic protein-1 receptor CCR2 in macrophages associated with human ovarian carcinoma. J Immunol vol. 164, (2) 733-738.
10.4049/jimmunol.164.2.733
Balkwill F(1999). TNF biosynthesis in gut associated immunopathologies. Gut vol. 45, (4)
10.1136/gut.45.4.483
Thavasu P, Propper D, McDonald A et al.(1999). The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients. Cancer Res vol. 59, (16) 3980-3984.
Turner L, Scotton C, Negus R et al.(1999). Hypoxia inhibits macrophage migration. European Journal of Immunology vol. 29, (7) 2280-2287.
10.1002/(SICI)1521-4141(199907)29:07&lt;2280::AID-IMMU2280&gt;3.0.CO;2-C
Turner L, Scotton C, Negus R et al.(1999). Hypoxia inhibits macrophage migration. Eur J Immunol vol. 29, (7) 2280-2287.
10.1002/(SICI)1521-4141(199907)29:07<2280::AID-IMMU2280>3.0.CO;2-C
Moore RJ, Owens DM, Stamp G et al.(1999). Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med vol. 5, (7) 828-831.
10.1038/10552
Burke F, Smith PD, Crompton MR et al.(1999). Cytotoxic response of ovarian cancer cell lines to IFN-gamma is associated with sustained induction of IRF-1 and p21 mRNA. Br J Cancer vol. 80, (8) 1236-1244.
10.1038/sj.bjc.6690491
Boyd RS, Balkwill FR(1999). MMP-2 release and activation in ovarian carcinoma: the role of fibroblasts. Br J Cancer vol. 80, (3-4) 315-321.
10.1038/sj.bjc.6690357
Moore RJ, Owens DM, Stamp G et al.(1999). Erratum: Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis (Nature Medicine (1999) 5 (828-831)). Nature Medicine vol. 5, (9)
Dias S, Boyd R, Balkwill F(1998). IL-12 regulates VEGF and MMPs in a murine breast cancer model. International Journal of Cancer vol. 78, (3) 361-365.
10.1002/(SICI)1097-0215(19981029)78:3&lt;361::AID-IJC17&gt;3.0.CO;2-9
Dias S, Boyd R, Balkwill F(1998). IL-12 regulates VEGF and MMPs in a murine breast cancer model. Int J Cancer vol. 78, (3) 361-365.
10.1002/(SICI)1097-0215(19981029)78:3<361::AID-IJC17>3.0.CO;2-9
Leber TM, Balkwill FR(1998). Regulation of monocyte MMP-9 production by TNF-alpha and a tumour-derived soluble factor (MMPSF). Br J Cancer vol. 78, (6) 724-732.
10.1038/bjc.1998.568
Negus RP, Turner L, Burke F et al.(1998). Hypoxia down-regulates MCP-1 expression: implications for macrophage distribution in tumors. J Leukoc Biol vol. 63, (6) 758-765.
10.1002/jlb.63.6.758
Dias S, Thomas H, Balkwill F(1998). Multiple molecular and cellular changes associated with tumour stasis and regression during IL-12 therapy of a murine breast cancer model. International Journal of Cancer vol. 75, (1) 151-157.
10.1002/(SICI)1097-0215(19980105)75:1&lt;151::AID-IJC23&gt;3.0.CO;2-I
Dias S, Thomas H, Balkwill F(1998). Multiple molecular and cellular changes associated with tumour stasis and regression during IL-12 therapy of a murine breast cancer model. Int J Cancer vol. 75, (1) 151-157.
10.1002/(SICI)1097-0215(19980105)75:1<151::AID-IJC23>3.0.CO;2-I
Balkwill F(1998). The molecular and cellular biology of the chemokines. J Viral Hepat vol. 5, (1) 1-14.
10.1046/j.1365-2893.1998.00081.x
(1998). United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). Br J Cancer vol. 77, (1) 1-10.
10.1038/bjc.1998.1
Leber TM, Balkwill FR(1997). Zymography: a single-step staining method for quantitation of proteolytic activity on substrate gels. Anal Biochem vol. 249, (1) 24-28.
10.1006/abio.1997.2170
Burke F, East N, Upton C et al.(1997). Interferon gamma induces cell cycle arrest and apoptosis in a model of ovarian cancer: enhancement of effect by batimastat. Eur J Cancer vol. 33, (7) 1114-1121.
10.1016/S0959-8049(97)88065-3
Negus RP, Stamp GW, Hadley J et al.(1997). Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol vol. 150, (5) 1723-1734.
Balkwill F, Pitha PM (1997). Interferons and cytokines on a grand scale. Cytokine Growth Factor Rev. vol. 8, 91-95.
10.1016/S1359-6101(96)00051-2
Balkwill F(1997). Cytokine amplification and inhibition of immune and inflammatory responses. J Viral Hepat vol. 4 Suppl 2, 6-15.
10.1111/j.1365-2893.1997.tb00175.x
Zucker S(1996). Correspondence re: N-B. Liabakk et al., matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res., 56: 190-196, 1966. Cancer Res vol. 56, (15)
Burke F, Relf M, Negus R et al.(1996). A cytokine profile of normal and malignant ovary. Cytokine vol. 8, (7) 578-585.
10.1006/cyto.1996.0077
Balkwill FR(1996). Cytokines in Hemopoiesis, Oncology and Immunology III. British Journal of Cancer vol. 73, (5) 711-711.
10.1038/bjc.1996.124
Thomas H, Hanby AM, Smith RA et al.(1996). An inbred colony of oncogene transgenic mice: diversity of tumours and potential as a therapeutic model. Br J Cancer vol. 73, (1) 65-72.
10.1038/bjc.1996.12
Burke F, Balkwill FR(1996). Cytokines in animal models of cancer. Biotherapy vol. 8, (3-4) 229-241.
10.1007/BF01877209
Negus RP, Balkwill FR(1996). Cytokines in tumour growth, migration and metastasis. World J Urol vol. 14, (3) 157-165.
10.1007/BF00186895
Liabakk NB, Talbot I, Smith RA et al.(1996). Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res vol. 56, (1) 190-196.
Balkwill F(1995). Making sense. Nature vol. 378, (6554)
10.1038/378318b0
de Kossodo S, Moore R, Gschmeissner S et al.(1995). Changes in endogenous cytokines, adhesion molecules and platelets during cytokine-induced tumour necrosis. Br J Cancer vol. 72, (5) 1165-1172.
10.1038/bjc.1995.481
Thomas H, Balkwill F(1995). Assessing new anti-tumour agents and strategies in oncogene transgenic mice. Cancer Metastasis Rev vol. 14, (2) 91-95.
10.1007/BF00665793
Burger D, Dayer JM(1995). Inhibitory cytokines and cytokine inhibitors. Neurology vol. 45, (6 Suppl 6) S39-S43.
10.1212/WNL.45.6_Suppl_6.S39
Negus RP, Stamp GW, Relf MG et al.(1995). The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J Clin Invest vol. 95, (5) 2391-2396.
10.1172/JCI117933
Thavasu PW, Ganjoo RK, Maidment SA et al.(1995). Multiple myeloma: an immunoclinical study of disease and response to treatment. Hematol Oncol vol. 13, (2) 69-82.
10.1002/hon.2900130204
Burke F, Knowles RG, East N et al.(1995). The role of indoleamine 2,3-dioxygenase in the anti-tumour activity of human interferon-gamma in vivo. Int J Cancer vol. 60, (1) 115-122.
10.1002/ijc.2910600117
Balkwill F(1995). Tumour necrosis factor in ovarian cancer. Interferons and Cytokines (26) 6-8.
Balkwill FR(1994). Cytokine therapy of cancer. The importance of knowing the context. Eur Cytokine Netw vol. 5, (4) 379-385.
Naylor MS, Stamp GW, Davies BD et al.(1994). Expression and activity of MMPS and their regulators in ovarian cancer. Int J Cancer vol. 58, (1) 50-56.
10.1002/ijc.2910580110
Miles D, Thomsen L, Balkwill F et al.(1994). Association between biosynthesis of nitric oxide and changes in immunological and vascular parameters in patients treated with interleukin-2. Eur J Clin Invest vol. 24, (4) 287-290.
10.1111/j.1365-2362.1994.tb01087.x
Miles DW, Happerfield LC, Naylor MS et al.(1994). Expression of tumour necrosis factor (TNF alpha) and its receptors in benign and malignant breast tissue. Int J Cancer vol. 56, (6) 777-782.
10.1002/ijc.2910560603
Thomas H, Balkwill FR(1994). Oncogene transgenic mice as therapeutic models in cancer research. Eur J Cancer vol. 30A, (4) 533-537.
10.1016/0959-8049(94)90434-0
Philip PA, Rea D, Thavasu P et al.(1993). Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee. J Natl Cancer Inst vol. 85, (22) 1812-1818.
10.1093/jnci/85.22.1812
Davies B, Waxman J, Wasan H et al.(1993). Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res vol. 53, (22) 5365-5369.
Davies B, Brown PD, East N et al.(1993). A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res vol. 53, (9) 2087-2091.
Davies B, Miles DW, Happerfield LC et al.(1993). Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer vol. 67, (5) 1126-1131.
10.1038/bjc.1993.207
Naylor MS, Stamp GW, Foulkes WD et al.(1993). Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest vol. 91, (5) 2194-2206.
10.1172/JCI116446
Taylor-Papadimitriou J, Balkwill F(1993). Cancer. Fusion potential for vaccines. Nature vol. 362, (6422)
10.1038/362695a0
Balkwill F (1993). Cytokines in health and disease. Immunol Today. vol. 14, 149-150.
10.1016/0167-5699(93)90228-D
Burke F, Stuart Naylor M, Davies B et al.(1993). The cytokine wall chart. Trends in Immunology vol. 14, (4)
Burke F, Naylor MS, Davies B et al.(1993). The cytokine wall chart. Immunol Today vol. 14, (4) 165-170.
10.1016/0167-5699(93)90280-X
Saraya KA, Balkwill FR(1993). Temporal sequence and cellular origin of interleukin-2 stimulated cytokine gene expression. Br J Cancer vol. 67, (3) 514-521.
10.1038/bjc.1993.96
Balkwill F(1993). Tumour necrosis factor. Improving on the formula. Nature vol. 361, (6409) 206-207.
10.1038/361206a0
Balkwill F(1993). Cytokines in health and disease. Trends in Immunology vol. 14, (4) 149-150.
Balkwill F(1993). Improving on the formula. Nature vol. 361, (6409) 206-207.
10.1038/361206a0
Burke F, Griffin D, Elwood N et al.(1993). The effect of cytokines on cultured mononuclear cells from patients with B cell chronic lymphocytic leukemia. Hematol Oncol vol. 11, (1) 23-33.
10.1002/hon.2900110104
Miles DW, Aderka D, Engelmann H et al.(1992). Induction of soluble tumour necrosis factor receptors during treatment with interleukin-2. Br J Cancer vol. 66, (6) 1195-1199.
10.1038/bjc.1992.435
Thavasu PW, Longhurst S, Joel SP et al.(1992). Measuring cytokine levels in blood. Importance of anticoagulants, processing, and storage conditions. J Immunol Methods vol. 153, (1-2) 115-124.
10.1016/0022-1759(92)90313-I
Naylor MS, Stamp GW, Balkwill FR(1992). Beta actin expression and organization of actin filaments in colorectal neoplasia. Epithelial Cell Biol vol. 1, (3) 99-104.
Malik ST, East N, Boraschi D et al.(1992). Effects of intraperitoneal recombinant interleukin-1 beta in intraperitoneal human ovarian cancer xenograft models: comparison with the effects of tumour necrosis factor. Br J Cancer vol. 65, (5) 661-666.
10.1038/bjc.1992.141
Malik ST, Balkwill FR(1992). Antiproliferative and antitumor activity of TNF in vitro and in vivo. Immunol Ser vol. 56, 239-268.
Balkwill FR(1992). Tumour necrosis factor and cancer. Prog Growth Factor Res vol. 4, (2) 121-137.
10.1016/0955-2235(92)90027-F
Malik ST, Knowles RG, East N et al.(1991). Antitumor activity of gamma-interferon in ascitic and solid tumor models of human ovarian cancer. Cancer Res vol. 51, (24) 6643-6649.
Miles DW, Longhurst SJ, Harper PG et al.(1991). Toxicity and reconstitution of recombinant interleukin-2 with albumin. Lancet vol. 338, (8780)
10.1016/0140-6736(91)92770-3
Thomas H, Balkwill FR(1991). Effects of interferons and other cytokines on tumors in animals: a review. Pharmacol Ther vol. 52, (3) 307-330.
10.1016/0163-7258(91)90030-P
Malik S, Balkwill F(1991). Epithelial ovarian cancer: a cytokine propelled disease?. Br J Cancer vol. 64, (4) 617-620.
10.1038/bjc.1991.372
Kelly SA, Gschmeissner S, East N et al.(1991). Enhancement of metastatic potential by gamma-interferon. Cancer Res vol. 51, (15) 4020-4027.
Stanley LA, Adams DJ, Balkwill FR et al.(1991). Differential effects of recombinant interferon alpha on constitutive and inducible cytochrome P450 isozymes in mouse liver. Biochem Pharmacol vol. 42, (2) 311-320.
10.1016/0006-2952(91)90718-K
Lagadec PF, Saraya KA, Balkwill FR(1991). Human small-cell lung-cancer cells are cytokine-resistant but NK/LAK-sensitive. Int J Cancer vol. 48, (2) 311-317.
10.1002/ijc.2910480226
Malik ST, Martin D, Hart I et al.(1991). Therapy of human ovarian cancer xenografts with intraperitoneal liposome encapsulated muramyl-tripeptide phosphoethanolamine (MTP-PE) and recombinant GM-CSF. Br J Cancer vol. 63, (3) 399-403.
10.1038/bjc.1991.92
Naylor MS, Stamp GW, Balkwill FR(1990). Investigation of cytokine gene expression in human colorectal cancer. Cancer Res vol. 50, (14) 4436-4440.
Miles DW, Bird CR, Wadhwa M et al.(1990). Reconstitution of interleukin 2 with albumin for infusion. Lancet vol. 335, (8705) 1602-1603.
10.1016/0140-6736(90)91439-H
Malik ST, Naylor MS, East N et al.(1990). Cells secreting tumour necrosis factor show enhanced metastasis in nude mice. Eur J Cancer vol. 26, (10) 1031-1034.
10.1016/0277-5379(90)90044-T
Naylor MS, Malik ST, Stamp GW et al.(1990). In situ detection of tumour necrosis factor in human ovarian cancer specimens. Eur J Cancer vol. 26, (10) 1027-1030.
10.1016/0277-5379(90)90043-S
Malik ST, Griffin DB, Naylor MS et al.(1990). The complex effects of recombinant tumour necrosis factor-alpha (rhTNF-alpha) in human ovarian cancer xenograft models. Prog Clin Biol Res vol. 349, 393-403.
Balkwill FR, Naylor MS, Malik S(1990). Tumour necrosis factor as an anticancer agent. Eur J Cancer vol. 26, (5) 641-644.
10.1016/0277-5379(90)90097-D
Malik ST, Griffin DB, Fiers W et al.(1989). Paradoxical effects of tumour necrosis factor in experimental ovarian cancer. Int J Cancer vol. 44, (5) 918-925.
10.1002/ijc.2910440529
Balkwill FR, Griffin DB, Lee AE(1989). Interferons alpha and gamma differ in their ability to cause tumour stasis and regression in vivo. Eur J Cancer Clin Oncol vol. 25, (10) 1481-1486.
10.1016/0277-5379(89)90108-9
Balkwill FR, Burke F(1989). The cytokine network. Immunol Today vol. 10, (9) 299-304.
10.1016/0167-5699(89)90085-6
Balkwill FR(1989). Interferons. Lancet vol. 1, (8646) 1060-1063.
10.1016/S0140-6736(89)92455-0
Balkwill FR(1989). Tumour necrosis factor. Br Med Bull vol. 45, (2) 389-400.
10.1093/oxfordjournals.bmb.a072330
Ramani P, Balkwill FR(1989). Action of recombinant alpha interferon against experimental and spontaneous metastases in a murine model. Int J Cancer vol. 43, (1) 140-146.
10.1002/ijc.2910430126
Stebbings WS, Vinson GP, Farthing MJ et al.(1989). Effect of steroid hormones on human colorectal adenocarcinoma xenografts, of known steroid-receptor status, in nude mice. J Cancer Res Clin Oncol vol. 115, (5) 439-444.
10.1007/BF00393333
Fiers W, Balkwill FR(1989). Future prospects and problems. Cancer Surv vol. 8, (4) 921-927.
Kelly SA, Malik ST, Balkwill FR(1989). The relevance of animal tumour models to the preclinical screening of cytokines. Cancer Surv vol. 8, (4) 741-754.
Balkwill F(1988). Cytokines--soluble factors in immune responses. Curr Opin Immunol vol. 1, (2) 241-249.
10.1016/0952-7915(88)90008-8
Ramani P, Balkwill FR(1988). Human interferons inhibit experimental metastases of a human melanoma cell line in nude mice. Br J Cancer vol. 58, (3) 350-354.
10.1038/bjc.1988.217
Fentiman IS, Balkwill FR, Thomas BS et al.(1988). An autoimmune aetiology for hypothyroidism following interferon therapy for breast cancer. Eur J Cancer Clin Oncol vol. 24, (8) 1299-1303.
10.1016/0277-5379(88)90219-2
Malik S, Balkwill F(1988). The anti-cancer activity of tumour necrosis factor. Ann Inst Pasteur Immunol vol. 139, (3) 285-288.
Malik S, Balkwill FR(1988). Tumour necrosis factor. Br Med J (Clin Res Ed) vol. 296, (6631)
10.1136/bmj.296.6631.1214
Ramani P, Balkwill FR(1987). Enhanced metastases of a mouse carcinoma after in vitro treatment with murine interferon gamma. Int J Cancer vol. 40, (6) 830-834.
10.1002/ijc.2910400621
Balkwill F, Osborne R, Burke F et al.(1987). Evidence for tumour necrosis factor/cachectin production in cancer. Lancet vol. 2, (8570) 1229-1232.
10.1016/S0140-6736(87)91850-2
Tilles JG, Balkwill F, Davilla J(1987). 2',5'-Oligoadenylate synthetase and interferon in peripheral blood after rubella, measles, or mumps live virus vaccine. Proc Soc Exp Biol Med vol. 186, (1) 70-74.
10.3181/00379727-186-42586
Fentiman IS, Balkwill FR, Cuzick J et al.(1987). A trial of human alpha interferon as an adjuvant agent in breast cancer after loco-regional recurrence. Eur J Surg Oncol vol. 13, (5) 425-428.
Balkwill FR, Ward BG, Moodie E et al.(1987). Therapeutic potential of tumor necrosis factor-alpha and gamma-interferon in experimental human ovarian cancer. Cancer Res vol. 47, (18) 4755-4758.
Balkwill FR, Smyth JF(1987). Interferons in cancer therapy: a reappraisal. Lancet vol. 2, (8554) 317-319.
10.1016/S0140-6736(87)90901-9
Smyth JF, Balkwill FR, Cavalli F et al.(1987). Interferons in oncology: current status and future directions. Eur J Cancer Clin Oncol vol. 23, (6) 887-889.
10.1016/0277-5379(87)90298-7
Dealtry GB, Naylor MS, Fiers W et al.(1987). The effect of recombinant human tumour necrosis factor on growth and macromolecular synthesis of human epithelial cells. Exp Cell Res vol. 170, (2) 428-438.
10.1016/0014-4827(87)90318-1
Ward BG, Wallace K, Shepherd JH et al.(1987). Intraperitoneal xenografts of human epithelial ovarian cancer in nude mice. Cancer Res vol. 47, (10) 2662-2667.
Dealtry GB, Naylor MS, Fiers W et al.(1987). DNA fragmentation and cytotoxicity caused by tumor necrosis factor is enhanced by interferon-gamma. Eur J Immunol vol. 17, (5) 689-693.
10.1002/eji.1830170517
Adams DJ, Balkwill FR, Griffin DB et al.(1987). Induction and suppression of glutathione transferases by interferon in the mouse. J Biol Chem vol. 262, (10) 4888-4892.
Balkwill FR, Ward BG, Fiers W(1987). Effects of tumour necrosis factor on human tumour xenografts in nude mice. Ciba Found Symp vol. 131, 154-169.
Balkwill FR, Stevens MH, Griffin DB et al.(1987). Interferon gamma regulates HLA-D expression on solid tumors in vivo. Eur J Cancer Clin Oncol vol. 23, (1) 101-106.
10.1016/0277-5379(87)90426-3
Rowlinson G, Balkwill F, Snook D et al.(1986). Enhancement by gamma-interferon of in vivo tumor radiolocalization by a monoclonal antibody against HLA-DR antigen. Cancer Res vol. 46, (12 Pt 1) 6413-6417.
Carmichael J, Fergusson RJ, Wolf CR et al.(1986). Augmentation of cytotoxicity of chemotherapy by human alpha-interferons in human non-small cell lung cancer xenografts. Cancer Res vol. 46, (10) 4916-4920.
Balkwill FR, Proietti E(1986). Effects of mouse interferon on human tumour xenografts in the nude mouse host. Int J Cancer vol. 38, (3) 375-380.
10.1002/ijc.2910380312
Balkwill FR(1986). Interferons: from molecular biology to man. Part 3. Interferons and disease. Microbiol Sci vol. 3, (9) 281-284.
Balkwill FR, Lee A, Aldam G et al.(1986). Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons. Cancer Res vol. 46, (8) 3990-3993.
Balkwill FR(1986). Interferons: from molecular biology to man. Part 2. Interferons and cell function. Microbiol Sci vol. 3, (8) 229-233.
Balkwill FR(1986). Interferons: from molecular biology to man. Part 1. Genetics and molecular biology of the interferon system. Microbiol Sci vol. 3, (7) 212-215.
Ramani P, Hart IR, Balkwill FR(1986). The effect of interferon on experimental metastases in immunocompetent and immunodeficient mice. Int J Cancer vol. 37, (4) 563-568.
10.1002/ijc.2910370415
Balkwill FR(1986). Animal models for investigating antitumor effects of interferon. Methods Enzymol vol. 119, 649-657.
10.1016/0076-6879(86)19087-2
Taylor-Papadimitriou J, Balkwill F, Ebsworth N et al.(1985). Antiviral and antiproliferative effects of interferons in quiescent fibroblasts are dissociable. Virology vol. 147, (2) 405-412.
10.1016/0042-6822(85)90142-4
Fentiman IS, Thomas BS, Balkwill FR et al.(1985). Primary hypothyroidism associated with interferon therapy of breast cancer. Lancet vol. 1, (8438)
10.1016/S0140-6736(85)92475-4
Balkwill FR, Goldstein L, Stebbing N(1985). Differential action of six human interferons against two human carcinomas growing in nude mice. Int J Cancer vol. 35, (5) 613-617.
10.1002/ijc.2910350508
Bye A, Balkwill F, Brigden D et al.(1985). Use of interferon in the management of patients with subacute sclerosing panencephalitis. Dev Med Child Neurol vol. 27, (2) 170-175.
10.1111/j.1469-8749.1985.tb03766.x
Rohatiner AZ, Prior P, Burton A et al.(1985). Central nervous system toxicity of interferon. Prog Exp Tumor Res vol. 29, 197-202.
Padmanabhan N, Balkwill FR, Bodmer JG et al.(1985). Recombinant DNA human interferon alpha 2 in advanced breast cancer: a phase 2 trial. Br J Cancer vol. 51, (1) 55-60.
10.1038/bjc.1985.8
Shearer M, Taylor-Papadimitriou J, Griffin D et al.(1984). Monoclonal antibodies that distinguish between subspecies of human interferon-alpha and that detect interferon oligomers. J Immunol vol. 133, (6) 3096-3101.
Balkwill FR, Bokhon'ko AI(1984). Differential effects of pure human alpha and gamma interferons on fibroblast cell growth and the cell cycle. Exp Cell Res vol. 155, (1) 190-197.
10.1016/0014-4827(84)90780-8
Balkwill FR, Mowshowitz S, Seilman SS et al.(1984). Positive interactions between interferon and chemotherapy due to direct tumor action rather than effects on host drug-metabolizing enzymes. Cancer Res vol. 44, (11) 5249-5255.
Balkwill FR, Moodie EM(1984). Positive interactions between human interferon and cyclophosphamide or adriamycin in a human tumor model system. Cancer Res vol. 44, (3) 904-908.
Borden EC, Balkwill FR(1984). Preclinical and clinical studies of interferons and interferon inducers in breast cancer. Cancer vol. 53, (3 Suppl) 783-789.
10.1002/1097-0142(19840201)53:3+<783::AID-CNCR2820531329>3.0.CO;2-I
Borden EC, Balkwill FR(1984). Preclinical and clinical studies of interferons and interferon inducers in breast cancer. Cancer vol. 53, (3 S) 783-789.
10.1002/1097-0142(19840201)53:3+&lt;783::AID-CNCR2820531329&gt;3.0.CO;2-I
Rohatiner AZ, Prior PF, Burton AC et al.(1983). Central nervous system toxicity of interferon. Br J Cancer vol. 47, (3) 419-422.
10.1038/bjc.1983.63
Balkwill FR, Griffin DB, Band HA et al.(1983). Immune human lymphocytes produce an acid-labile alpha-interferon. J Exp Med vol. 157, (3) 1059-1063.
10.1084/jem.157.3.1059
McCance DJ, Sebesteny A, Griffin BE et al.(1983). A paralytic disease in nude mice associated with polyoma virus infection. J Gen Virol vol. 64 (Pt 1), 57-67.
10.1099/0022-1317-64-1-57
Balkwill FR, Moodie EM, Freedman V et al.(1983). An Animal Model System for Investigating the AntiTumor Effects of Human Interferon. Journal of Interferon Research vol. 3, (3) 319-326.
10.1089/jir.1983.3.319
Rohatiner AZ, Balkwill FR, Malpas JS et al.(1983). Experience with human lymphoblastoid interferon in acute myelogenous leukaemia (AML). Cancer Chemother Pharmacol vol. 11, (1) 56-58.
10.1007/BF00257419
Rohatiner AZ, Balkwill F, Lister TA(1983). Interferon in acute myelogenous leukaemia: a preliminary report. Haematol Blood Transfus vol. 28, 56-58.
Taylor-Papadimitriou J, Balkwill FR(1982). Implications for clinical application of new developments in interferon research. Biochim Biophys Acta vol. 695, (1) 49-67.
10.1016/0304-419X(82)90006-3
Balkwill FR, Moodie EM, Freedman V et al.(1982). Human interferon inhibits the growth of established human breast tumours in the nude mouse. Int J Cancer vol. 30, (2) 231-235.
10.1002/ijc.2910300217
Silverman RH, Watling D, Balkwill FR et al.(1982). The ppp(A2'p)nA and protein kinase systems in wild-type and interferon-resistant Daudi cells. Eur J Biochem vol. 126, (2) 333-341.
10.1111/j.1432-1033.1982.tb06783.x
Rohatiner AZ, Balkwill FR, Griffin DB et al.(1982). A phase I study of human lymphoblastoid interferon administered by continuous intravenous infusion. Cancer Chemother Pharmacol vol. 9, (2) 97-102.
10.1007/BF00265387
Taylor-Papadimitriou J, Shearer M, Balkwill FR et al.(1982). Effects of HuIFN-alpha 2 and HuIFN-alpha (Namalwa) on breast cancer cells grown in culture and as xenografts in the nude mouse. J Interferon Res vol. 2, (4) 479-491.
10.1089/jir.1982.2.479
Balkwill FH(1981). Extracts from the last century. Mechanical dentistry--on regulation cases by F.H. Balkwill. Br Dent J vol. 151, (1)
10.1038/sj.bdj.4804620
Hogg N, Balkwill FR(1981). Species restriction in cytostatic activity of human and murine monocytes and macrophages. Immunology vol. 43, (1) 197-204.
Rohatiner A, Balkwill F, Malpas JS et al.(1981). A phase I study of human lymphoblastoid interferon in patients with hematological malignancies. Haematol Blood Transfus vol. 26, 63-67.
Rohatiner AZS, Balkwill F, Malpas JS et al.(1981). A phase I study of intravenous human lymphoblastoid interferon (HLBI). Proceedings of the American Association for Cancer Research vol. Vol. 22,
Sebesteny A, Tilly R, Balkwill F et al.(1980). Demyelination and wasting associated with polyomavirus infection in nude (nu/nu) mice. Lab Anim vol. 14, (4) 337-345.
10.1258/002367780781071021
Balkwill F, Taylor-Papadimitriou J, Fantes KH et al.(1980). Human lymphoblastoid interferon can inhibit the growth of human breast cancer xenografts in athymic (nude) mice. Eur J Cancer vol. 16, (4) 569-573.
10.1016/0014-2964(80)90237-6
Balkwill F, Taylor Papadimitriou J, Fantes KH et al.(1980). HUMAN LYMPHOBLASTOID INTERFERON CAN INHIBIT THE GROWTH OF HUMAN BREAST CANCER XENOGRAFTS IN ATHYMIC [NUDE] MICE. Annals of the New York Academy of Sciences vol. 350, (1) 591-592.
10.1111/j.1749-6632.1980.tb20671.x
Balkwill FR, Oliver RT(1979). Remission in acute myeloblastic leukaemia. Lancet vol. 2, (8149) 961-962.
10.1016/S0140-6736(79)92658-8
Balkwill FR, Hogg N(1979). Characterization of human breast milk macrophages cytostatic for human cell lines. J Immunol vol. 123, (4) 1451-1456.
Balkwill FR(1979). Interferons as cell-regulatory molecules. Cancer Immunology Immunotherapy vol. 7, (1) 7-14.
10.1007/BF00205403
Balkwill F, Watling D, Taylor-Papadimitriou J(1978). Inhibition by lymphoblastoid interferon of growth of cells derived from the human breast. Int J Cancer vol. 22, (3) 258-265.
10.1002/ijc.2910220307
Balkwill F, Taylor-Papadimitriou J(1978). Interferon affects both G1 and S+G2 in cells stimulated from quiescence to growth. Nature vol. 274, (5673) 798-800.
10.1038/274798a0
Balkwill FR, Oliver RT(1977). Growth inhibitory effects of interferon on normal and malignant human haemopoietic cells. Int J Cancer vol. 20, (4) 500-505.
10.1002/ijc.2910200405
Franks CR, Bishop D, Balkwill FR et al.(1977). Growth of acute myeloid leukaemia as discrete subcutaneous tumours in immune-deprived mice. Br J Cancer vol. 35, (5) 697-700.
10.1038/bjc.1977.107
Balkwill FR, Franks CR, Oliver RT et al.(1977). Neoplastic macrophages grown from human leukaemic monocytes. J Pathol vol. 122, (1) 13-26.
10.1002/path.1711220104
Balkwill FR, Oliver RT(1976). Diagnostic and prognostic significance of peripheral blood cultural characteristics in adult acute leukaemia. Br J Cancer vol. 33, (4) 400-410.
10.1038/bjc.1976.65
Balkwill FR, Oliver RT(1976). Morphological characterisation of adult acute leukaemia in short-term liquid culture. Recent Results Cancer Res (56) 87-90.
Balkwill F, Pindar A, Crowther D(1974). Factors influencing microculture in leukaemia cells. Nature vol. 251, (5477) 741-742.
10.1038/251741a0
Return to top